InsituGen is redefining steroid hormone diagnostics through a multi-patented, breakthrough bioassay platform that detects hormone activity where current technologies fail. Existing endocrine tests are slow, insensitive, expensive, and unable to measure functional bioactivity or detect unknown hormonal mimics. InsituGen eliminates these limitations, opening an addressable market valued at more than US$21B across animal health, human health, environmental monitoring, and consumer product safety. 

The company’s first commercial product—NeuterReady™—has launched in New Zealand and the UK, providing veterinarians and pet owners with rapid, accurate detection of hormonal maturity. This directly addresses a >US$2B unmet medical need in companion animal hormone health. More than 100 million dogs globally are neutered or spayed without hormonal assessment, and current tests are unable to guide optimal timing. InsituGen solves this gap and is advancing a full suite of life-stage diagnostics including SpayReady, SpayCheck, and LongevityAnnual. 

InsituGen has delivered milestones across successive investment rounds and is now raising NZ$2M to scale commercial rollout, expand globally into AUS, Germany and the US, and accelerate point-of-care development. With strong recurring revenue potential, multi-vertical applications, no direct competition, and a globally scalable platform, InsituGen offers investors the opportunity to participate early in a technology poised to transform hormone-based diagnostics. 

To learn more about this opportunity and speak with one of the Pacific Channel team, register your interest below.